---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-22-000083"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2022-07-19T23:59:59+00:00"
generated_at: "2026-06-24T12:56:56.934702+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Exelixis sues MSN for generic CABOMETYX, asserting new patent expiring 2032

## Summary
- Filed patent infringement suit against MSN for generic CABOMETYX, asserting U.S. Patent No. 11,298,349 (expires Feb 10, 2032).
- This is the fourth case; prior cases involve patents expiring Oct 8, 2030 and Jan 15, 2030, with trials in May 2022 (pending) and May 2023.
- Exelixis seeks injunction to block FDA approval of MSN's ANDA until expiration of the asserted patents.
- No trial date set for this new case; litigation ongoing in Delaware District Court.

## SEC filing metadata
- accession: 0000939767-22-000083
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2022-07-19T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976722000083/0000939767-22-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976722000083/exel-20220718.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-22-000083
- JSON: https://secwatch.observer/filing/0000939767-22-000083.json
- Plain text: https://secwatch.observer/filing/0000939767-22-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.